Results 61 to 70 of about 166,627 (157)

Sicurezza e tollerabilità dei vaccini adiuvati con MF59

open access: yes, 2010
Vengono descritte le caratteristiche di efficacia e di sicurezza del vaccino adiuvato con mf59 dopo oltre 10 anni di ...
F. Pregliasco
core   +1 more source

Astragalus polysaccharide loaded MF59 adjuvant system enhances vaccine-induced cellular immune responses

open access: yesNano Research
Vaccine adjuvants play a pivotal role in enhancing immune responses, but traditional adjuvants such as MF59 primarily induce humoral immunity and exhibit limited ability to activate CD8+ T cell-mediated cellular immunity. To address this critical gap, we
Ying Zhu   +11 more
doaj   +1 more source

Intramuscular Inoculation of AS02-Adjuvanted Respiratory Syncytial Virus (RSV) F Subunit Vaccine Shows Better Efficiency and Safety Than Subcutaneous Inoculation in BALB/c Mice

open access: yesFrontiers in Immunology, 2022
We previously explored a panel of adjuvants formulated with pre-fusion RSV-F protein and found that AS02 may be a promising candidate adjuvant for developing RSV-F subunit vaccines with improved immunogenicity and desired immune response type.
Lijun Bian   +21 more
doaj   +1 more source

Development of a Novel Polyleucine‐Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus

open access: yesSmall, Volume 22, Issue 22, 17 April 2026.
Self‐assembling amphiphilic peptide L15K6 is used as a novel immunoadjuvant for the development of a Group A Streptococcus vaccine. Robust antigen‐specific IgG responses are generated and manage to kill isolated strains of Group A Streptococcus. Cellular and bulk RNA sequencing data reveals that L15K6 regulates immune responses potentially through TLR ...
Lantian Lu   +25 more
wiley   +1 more source

Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice

open access: yes, 2009
Pandemic H1N1 influenza vaccine antigens are currently being manufactured. The MF59 adjuvant has an established safety profile in humans and a proven ability to increase responses to some influenza vaccines in humans.
Daniele Casini   +19 more
core   +1 more source

A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease

open access: yesAdvanced Science, Volume 13, Issue 16, 18 March 2026.
This study developed a novel nano‐vaccine (Ferritin‐PC@PBNZs) comprising a ferritin‐based scaffold for the multivalent display of phosphorylcholine (PC) antigens, integrated with Prussian blue nanozymes (PBNZs) as a potent adjuvant. By leveraging the ferritin carrier for high‐density and ordered antigen display, the nano‐vaccine significantly augments ...
Jingyi Sheng   +6 more
wiley   +1 more source

The Squalene Oil‐in‐Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR‐Induced B‐Cell Responses

open access: yesCytometry Part A, Volume 109, Issue 3, Page 180-191, March 2026.
ABSTRACT For vaccination, the mechanisms of action of antigens and of immunostimulatory pathogen‐associated molecular pattern (PAMP) adjuvants are better understood than the roles of the depot, carrier, and other formulation‐related influences. Here, we carried out cytometric studies of vaccine formulations and the effect of adjuvant formulations on B ...
Egest J. Pone   +3 more
wiley   +1 more source

A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus

open access: yesFrontiers in Immunology
CpG oligodeoxynucleotides (CpG ODNs) boost the humoral and cellular immune responses to antigens through interaction with Toll-like receptor 9 (TLR9). These CpG ODNs have been extensively utilized in human vaccines. In our study, we evaluated five B-type
Yating Wang   +11 more
doaj   +1 more source

Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

open access: yes, 2015
Mass immunization of children has the potential to decrease infection rates and prevent the transmission of influenza. We evaluated the immunogenicity, safety, and tolerability of different formulations of cell-derived MF59-adjuvanted and nonadjuvanted A/
Pedotti, Paola   +8 more
core   +1 more source

Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention

open access: yesMedComm, Volume 7, Issue 3, March 2026.
This review focuses on the clinical features, molecular mechanisms, treatment methods, and preventive measures of the VZV, with the aim of providing a theoretical basis for the development of new treatment and prevention methods for HZ. ABSTRACT Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes ...
Lei Peng   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy